← Eichor
Condition: Richter Syndrome Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Richter Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL
Phase 2 · 16 location(s) · GELLC (Grupo Español de Leucemia Linfocítica Crónica) · NCT06926205Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572ONO-4538 Study in Patients With Richter's Transformation
Phase 2 · 10 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06936943Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Tr
Phase 2 · 11 location(s) · German CLL Study Group · NCT04271956Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Phase 2 · 3 location(s) · Aseel Alsouqi · NCT05873712Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · New York Medical College · NCT04491370Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chroni
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05536349A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · 32 location(s) · Miltenyi Biomedicine GmbH · NCT04792489Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transfor
Phase 2 · 5 location(s) · Christine Ryan · NCT06043674A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Phase 2 · 16 location(s) · University of Birmingham · NCT03899337CD45BE-HSPC + CART-45 Cells
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07451054Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg
Phase 1/Phase 2 · 29 location(s) · BeiGene · NCT05294731Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06863402Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Phase 2 · 4 location(s) · Weill Medical College of Cornell University · NCT04679012Registry of the German CLL Study Group
Phase N/A · 1 location(s) · German CLL Study Group · NCT02863692Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia o
Phase 2 · 3 location(s) · Mayo Clinic · NCT05388006Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter S
Phase 2 · 23 location(s) · French Innovative Leukemia Organisation · NCT06186648Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06735664
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.